Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Moorslede – page 108

2 287 clinical trials in Moorslede, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Moorslede at a glance
2 287
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 287 trials in Moorslede

Open in trial search

B-cell lymphoma+1

Not recruiting

Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Study on Luspatercept for Patients with Lower-risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

B-cell lymphoma

Not recruiting

Study of Glofitamab, Atezolizumab, and Polatuzumab Vedotin for Adults with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Pulmonary sarcoidosis

Not recruiting

Study on the Effects and Safety of Namilumab for Patients with Chronic Lung Sarcoidosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Namilumab
  • Sponsor:Kinevant Sciences GmbH

Study of Imetelstat in Patients with Low or Intermediate Risk Myelodysplastic Syndromes (MDS) Refractory to Erythropoiesis-Stimulating Agents

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imetelstat Sodium
  • Sponsor:Geron Corp.

Malignant melanoma

Not recruiting

Study on Melanoma Treatment: Comparing Encorafenib and Binimetinib with Ipilimumab and Nivolumab for Patients with BRAF V600 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Fungal infection

Not recruiting

Study on Rezafungin to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fluconazole
  • Sponsor:Mundipharma Research Limited

Study of Tepotinib and Osimertinib for Patients with Advanced or Metastatic Lung Cancer Resistant to Osimertinib Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Merck Healthcare KGaA

Study of Tepotinib for Patients with Advanced Lung Cancer with MET Exon 14 Skipping Alterations or MET Amplification

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tepotinib
  • Sponsor:Merck Healthcare KGaA

Study on Long-term Safety and Efficacy of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy Using a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Argenx

Hodgkin's disease+1

Not recruiting

Study on the Safety and Effectiveness of GEN3017 for Patients with Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Genmab A/S

Lupus nephritis

Not recruiting

Study on the Effectiveness and Safety of Obinutuzumab for Patients with Class III or IV Lupus Nephritis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Moorslede

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. This research evaluates different approaches to medication management for individuals with functional dyspepsia and reflux conditions.

  • PPI Deprescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Strategies

The research explores on-demand medication use and alternative therapeutic options, aiming to establish optimal treatment withdrawal protocols while maintaining patient comfort and health outcomes.

02 Digestive Health Studies

Clinical investigations centered on managing heartburn and related digestive conditions through innovative treatment approaches. The research examines the effectiveness of alginate-based alternatives and intermittent dosing strategies.

  • Medication Optimization
  • Alternative Therapies
  • Patient-Centered Approaches

This primary care research initiative aims to enhance treatment protocols for patients requiring long-term digestive health management.

03 Primary Care Innovation

Forward-thinking research in primary care settings exploring evidence-based approaches to medication management. The study compares traditional and innovative methods for reducing long-term medication dependency.

  • Clinical Practice Improvement
  • Patient Safety Protocols
  • Treatment Optimization

The research focuses on developing practical, patient-friendly approaches to medication reduction while maintaining therapeutic effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.